Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series
Novo Nordisk enters seventh year of partnership with Charlie Kimball to continue diabetes education and awareness with award-winning Race with Insulin® campaign
PLAINSBORO, N.J. and INDIANAPOLIS, Dec. 12, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams (CGRT), today announced a multi-year extension of their partnership, that will renew Novo Nordisk as the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the Verizon IndyCar Series.
Kimball, 29, from Camarillo, California, is the first and only licensed driver with diabetes in the history of INDYCAR to win a race at the most elite level of the series. Diagnosed in 2007, he monitors his blood sugar before, during, and after each race. Charlie also uses the Novo Nordisk prefilled insulin pens, Levemir® FlexTouch® (insulin detemir [rDNA origin] injection) and NovoLog® FlexPen® (insulin aspart [rDNA origin] injection), commonly represented on his car, to help manage his diabetes.
"Our partnership with Charlie and Chip Ganassi Racing Teams has given us the opportunity to convey that diabetes doesn't have to keep you from pursuing your dreams, and to inspire those who are working to manage their condition," said Camille Lee, senior vice president, Diabetes Marketing at Novo Nordisk. "We couldn't have picked two better partners to continue that journey."
The new agreement begins with the 2015 Verizon IndyCar Series, which marks the seventh consecutive year of partnership between Novo Nordisk and Kimball. Following two years of sponsorship of Kimball in the Indy Lights Series, Novo Nordisk partnered with CGRT to form Novo Nordisk Chip Ganassi Racing, and since December 2010, has been the title sponsor of Kimball in his Indy car.
"We are very pleased to have Novo Nordisk back with the team as they have been a tremendous partner of ours over the last four years," said Chip Ganassi, owner of Novo Nordisk Chip Ganassi Racing. "We also expect big things from Charlie as he continues to grow as a driver. We anticipate that 2015 will be a big year for the whole Novo Nordisk racing program."
Novo Nordisk has also been actively involved in providing information about diabetes awareness at INDYCAR events through the award-winning Race with Insulin® campaign. The sponsorship extension also retains the company's primary sponsorship of Kimball's race car, race suit, and other branding elements. Kimball will continue to make community and legislative appearances on behalf of Novo Nordisk throughout the term of the agreement to share his story and help educate the public on the importance of good diabetes control.
Kimball, who launched his racing career in 2002, has raced in several international series before moving to INDYCAR full time. He had a career-best INDYCAR season in 2013 with ten top-10 finishes and his first career win at Mid-Ohio and posted ten top-10 finishes in 2014.
Follow Kimball and his work with Novo Nordisk on Twitter @racewithinsulin or www.racewithinsulin.com.
What is Levemir® (insulin detemir [rDNA origin] injection)?
- Levemir® is a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.
- Levemir® is not meant for use to treat diabetic ketoacidosis.
Important Safety Information
Who should not take Levemir®?
Do not take Levemir® if:
- you have an allergy to Levemir® or any of the ingredients in Levemir®.
Before taking Levemir®, tell your health care provider about all your medical conditions including, if you are:
- pregnant, plan to become pregnant, or are breastfeeding.
- taking new prescription or over-the-counter medicines, including supplements.
Talk to your health care provider about how to manage low blood sugar.
How should I take Levemir®?
- Read the Instructions for Use and take exactly as directed.
- Know the type and strength of your insulin. Do not change your insulin type unless your health care provider tells you to.
- Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them.
- Do not share your Levemir® FlexTouch® with another person, even if the needle is changed. Do not reuse or share needles with another person. You may give another person an infection or get an infection from them.
- Never inject Levemir® into a vein or muscle.
What should I avoid while taking Levemir®?
- Do not drive or operate heavy machinery, until you know how it affects you.
- Do not drink alcohol or use medicines that contain alcohol.
What are the possible side effects of Levemir®?
Serious side effects can lead to death, including:
Low blood sugar. Some signs and symptoms include:
- anxiety, irritability, mood changes, dizziness, sweating, confusion, and headache.
Your insulin dose may need to change because of:
- change in level of physical activity, weight gain or loss, increased stress, illness, or change in diet.
Other common side effects may include:
- reactions at the injection site, itching, rash, serious allergic reactions (whole body reactions), skin thickening or pits at the injection site (lipodystrophy), weight gain, swelling of your hands and feet and if taken with thiazolidinediones (TZDs) possible heart failure.
Get emergency medical help if you have:
- trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please visit levemir.com for Prescribing Information.
Indications and Usage
What is NovoLog® (insulin aspart [rDNA origin] injection)?
- NovoLog® is a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.
Important Safety Information
Who should not take NovoLog®?
Do not take NovoLog® if:
- your blood sugar is too low (hypoglycemia) or you are allergic to any of its ingredients.
Before taking NovoLog®, tell your health care provider about all your medical conditions including, if you are:
- pregnant, plan to become pregnant, or are breastfeeding.
- taking new prescription or over-the-counter medicines, including supplements.
Talk to your health care provider about how to manage low blood sugar.
How should I take NovoLog®?
- Read the Instructions for Use and take exactly as directed.
- NovoLog® is fast-acting. Eat a meal within 5 to 10 minutes after taking it.
- Know the type and strength of your insulin. Do not change your insulin type unless your health care provider tells you to.
- Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them.
- Do not share your NovoLog® FlexPen® or FlexTouch®, PenFill® cartridge, or PenFill® cartridge device with another person, even if the needle is changed. Do not reuse or share needles with another person. You may give another person an infection or get an infection from them.
What should I avoid while taking NovoLog®?
- Do not drive or operate heavy machinery, until you know how NovoLog® affects you.
- Do not drink alcohol or use medicines that contain alcohol.
What are the possible side effects of NovoLog® (insulin aspart [rDNA origin] injection)?
Serious side effects can lead to death, including:
Low blood sugar. Some signs and symptoms include:
- anxiety, irritability, mood changes, dizziness, sweating, confusion, and headache.
Your insulin dose may need to change because of:
- weight gain or loss, increased stress, illness, or change in diet or level of physical activity.
Other common side effects may include:
- low potassium in your blood, injection site reactions, itching, rash, serious whole body allergic reactions, skin thickening or pits at the injection site, weight gain, and swelling of your hands and feet and if taken with thiazolidinediones (TZDs) possible heart failure.
Get emergency medical help if you have:
- trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please visit novolog.com for Prescribing Information.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk-us.com or follow our news in the United States on Twitter: @NovoNordiskUS.
About Diabetes
In the United States, 29.1 million people have diabetes,1 a condition in which the body does not produce enough or properly use insulin, the hormone needed to convert sugar, starches, and other food into energy needed for daily life.
About Chip Ganassi Racing
Chip Ganassi has been a fixture in the auto racing industry for over 25 years and is considered one of the most successful as well as innovative owners the sport has anywhere in the world. Today his teams include four cars in the Verizon INDYCAR Series, two cars in the NASCAR Sprint Cup Series, and one Prototype in the TUDOR United SportsCar Championship. Overall his teams have 17 championships and 160 victories, including four Indianapolis 500s, a Daytona 500, a Brickyard 400, five Rolex 24 At Daytonas, and the 12 Hours of Sebring. Ganassi boasts state-of-the-art race shop facilities in Indianapolis and Brownsburg, Indiana, and Concord, North Carolina, with a corporate office in Pittsburgh, Pennsylvania.
References
- CDC. National Diabetes Statistics Report, 2014. Centers for Disease Control website. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed October 6, 2014.
NovoLog®, Levemir®, FlexTouch®, FlexPen®, and PenFill® are registered trademarks of Novo Nordisk A/S.
© 2014 Novo Nordisk All rights reserved. 1114-00024305-1 December 2014
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novo-nordisk-and-chip-ganassi-racing-teams-announce-multi-year-sponsorship-agreement-for-verizon-indycar-series-300008755.html
SOURCE Novo Nordisk
Share this article